Clinical trials for muscular dystrophy
Reviewed by Extensive research is vital for improving and advancing knowledge about muscular dystrophy (MD). Clinical trials are research studies that evaluate the safety and effectiveness of medical devices, treatments, and approaches to care in people. Participants must meet specific medical and genetic eligibility criteria.
Participating in a trial can provide access to new medical interventions or allow evaluation of established therapies in new ways to improve health outcomes. Research teams follow strict protocols to protect your safety, monitor side effects, and gather accurate scientific data throughout the study.
If you or your child are considering an MD clinical trial, understanding study phases, potential benefits and risks, participant rights, and how to find legitimate trials can help you make an informed decision.
What is a muscular dystrophy clinical trial?
Clinical trials for MD are carefully designed medical research studies involving human volunteers that evaluate investigational treatments, gene therapies, medical devices, rehabilitation methods, or care strategies for different types of MD, such as Duchenne, Becker, myotonic dystrophy, or limb-girdle MD.
They allow medical researchers to evaluate whether these approaches are safe and effective. A study may test a completely new intervention or evaluate an established medication at a different dose or in a different combination.
Types of muscular dystrophy clinical trials
MD clinical trials can fall into several broad categories:
- Treatment trials: These assess the safety and effectiveness of potential MD treatments, including medicines, gene therapies, medical devices, and care strategies.
- Prevention trials: These explore ways to prevent or delay complications associated with MD. Depending on the type of MD, these studies may focus on approaches to preserve muscle function or prevent heart, respiratory, or other complications.
- Diagnostic trials: These trials study or compare tests and procedures used to diagnose MD or identify specific disease subtypes. These may include genetic tests, imaging, or other diagnostic approaches.
- Supportive care and quality of life trials: These studies evaluate approaches designed to improve daily functioning, comfort, or quality of life for people living with MD. These may include physical therapy, respiratory or cardiac care, assistive devices, or other supportive strategies.
What are the phases of clinical trials?
Clinical trials of investigational treatments are often conducted in phases.
Before an investigational treatment is tested in people, it is usually first tested on animals during preclinical research. This helps researchers assess its potential safety and effects before it is tested in people.
Each phase of a clinical trial has a different purpose. A study can be stopped if researchers identify unacceptable safety concerns at any phase.
Phase 1 clinical trials
In Phase 1, researchers assess the following:
- safety and tolerability
- appropriate dosing
- effects on your body
- early side effects of an intervention
This phase usually involves 20 to 100 healthy volunteers or people with MD and can last several months.
Phase 2 clinical trials
In Phase 2, researchers collect early information about whether an intervention may benefit people living with MD while they continue to evaluate its safety. Phase 2 studies usually include up to several hundred people with MD and can last anywhere from a few months to two years. Around 7 in 10 drugs reach Phase 2 trials.
Phase 3 clinical trials
Around one-third of drugs in Phase 2 testing move to Phase 3 trials, which study the effects of an intervention on between 300 and 3,000 people with MD for one to four years. In this phase, researchers collect further information about the benefits and risks of an intervention while they continue to monitor for side effects, including those that may take longer to appear.
Phase 4 clinical trials
Phase 4 studies take place after an intervention has been approved and can include several thousand volunteers with MD.
These studies can provide additional information about the safety and effectiveness of an intervention when it is used in the general population, outside well-controlled clinical trials with strict eligibility criteria. About 25-30% of clinical trials reach Phase 4.
Could a clinical trial be an option for my child or me?
To determine whether a study is a good fit, the research team carefully reviews a set of eligibility requirements that you or your child must meet. These rules protect safety and help ensure the study provides clear, accurate results. Requirements can vary from one MD clinical trial to another.
Scroll horizontally to view all columns -->
| Eligibility factor | What the research team assesses |
| MD type | Confirmation of your specific MD type, such as Duchenne. Carriers of genes without the disease may also be eligible for some studies. |
| Genetic changes | Specific gene mutations you have, which are verified through formal genetic testing for clinical trials or a copy of your genetic test results. |
| Age and sex | Whether you fit into the defined age brackets required by the study protocol. |
| Mobility status | Whether or not you have retained the ability to walk unassisted, or your levels of function without the ability to walk. |
| Disease stage | How far your condition has advanced, current muscle strength, daily functional ability, and symptom progression. |
| Steroid and medication use | Exact names and stable dosage history of corticosteroids or other drugs, along with any history of adverse drug reactions or allergies. |
| Heart health | How well your heart is functioning, including baseline heart rhythm and pumping strength, which is checked using an ECG or an echocardiogram. |
| Breathing function | Whether you or your child’s breathing function meets the study’s requirements by assessing pulmonary capacity metrics, such as forced vital capacity (FVC), or the need for nighttime breathing assistance. |
| Previous treatment | Prior exposure to gene therapies, investigational drugs, or surgical procedures, and your or your child’s response to those treatments. |
Diagnosis and genetic eligibility
Because MD includes several genetic conditions, many trials are designed for a specific disease type or genetic change. Therefore, you or your child may need genetic confirmation or previous genetic test results before you are enrolled in a trial.
Age, mobility, and disease stage
Clinical trials may have age and functional requirements. The research team may assess your or your child’s mobility and physical function using tests such as the six-minute walk test, which assesses the maximum distance a person can walk over a period of six minutes, or the 4-stair climb test, which measures how long it takes to climb four consecutive flights of stairs.
Current treatments and health requirements
Your or your child’s current and previous treatments may affect eligibility, as can your or your child’s heart and breathing function.
What happens before joining a clinical trial?
The research team may review your or your child’s diagnosis, test results, medical history, current treatments, and overall health.
You might undergo physical examinations, blood tests, heart or breathing assessments, and mobility tests during screening.
Screening can take time, and you or your child may not qualify even after traveling to the study site.
Informed consent and assent
Informed consent means receiving information about a trial before deciding whether to participate. The research team should explain the study, its procedures, potential risks and benefits, and alternatives, as well as give you an opportunity to ask questions.
You will most likely provide consent on your child’s behalf, but depending on the child’s age and circumstances, they may also be asked to provide assent.
Questions to ask the study coordinator
Before agreeing to join a clinical trial for yourself or your child, ask these essential questions during your screening or discussion around informed consent for a clinical trial.
- What is the trial’s goal, and is it testing a treatment, an intervention, or a new diagnostic test?
- How long will participation last?
- What is the chance of receiving a placebo?
- Could corticosteroids or other medications affect eligibility or require changes?
- What treatments are given, and what side effects are possible?
- Who should we contact about side effects outside clinic hours?
- How often are visits, and are remote options available?
- What costs and travel expenses are covered?
- How will personal information remain confidential?
- What happens if we leave the trial early?
During a muscular dystrophy clinical trial
The schedule depends on the study. Your visits may involve:
- receiving an investigational treatment
- monitoring for side effects
- physical examinations
- blood tests
- heart or breathing assessments
Measurements of muscle function
You may be assigned to different groups at random. One group may receive the investigational treatment, while another receives a placebo or another treatment.
However, many trials are blinded, meaning that you, the researchers, or both may not know which treatment you are receiving during part or all of the study.
Researchers use outcome measures to assess whether an intervention may be helping, and not knowing who received the investigational intervention or a placebo helps reduce the risk of bias. Only after the trial is complete will people know which intervention they received.
Depending on your type of MD, outcome measures may include:
- walking ability
- muscle strength
- breathing function
- heart function
- other measures of disease progression
Potential benefits and risks of clinical trials
You may benefit from access to an investigational treatment that is not yet approved for general use. Your participation may also help researchers better understand MD and develop future treatments.
However, participation does not guarantee that you or your child will benefit. Risks and downsides may include:
- Side effects and unknown risks: Investigational treatments may have side effects that are not yet fully understood. The research team should explain known and potential risks before you decide whether to participate.
- Placebo or control intervention: Some trials compare an investigational treatment with a placebo or another treatment. If you or your child are assigned to the placebo or control group, you may not receive the investigational treatment or its potential benefits. Ask the research team how participants are assigned to each group and what treatment the control group will receive.
- Travel, time, costs, and reimbursement: Trial visits and travel may affect work, school, or child care. Ask which expenses are reimbursed and what you may need to pay.
- Changes to existing treatment: Some trials may require changes to your or your child’s current treatment. Ask what changes are required and whether they will continue after the trial.
Participant rights and what happens after the trial
Participation in a clinical trial is voluntary. You can decide not to participate, and you may leave after enrolling. Talk with the research team before stopping an investigational treatment so you understand the appropriate next steps.
The research team should explain how information collected during the trial will be handled and who may have access to it. You can ask how your or your child’s personal and medical information will be protected.
Ask what happens when the trial ends. Some studies may include extension periods with additional follow-up visits. Also, access to the investigational treatment may or may not continue after the study.
How to find muscular dystrophy clinical trials
You can find different clinical trials as well as information about clinical trials on reputable clinical trial databases such as ClinicalTrials.gov, and the Muscular Dystrophy Association’s clinical trials webpage.
Contact the research team to confirm whether the study is currently recruiting and whether you may meet the clinical trial eligibility criteria.
How to evaluate whether a clinical trial is legitimate
A legitimate clinical trial should clearly explain its purpose, eligibility, procedures, risks and benefits, location, and contacts.
Be cautious if:
- you are pressured to enroll quickly
- you are asked to pay to take part in the trial
- a treatment is promised to work
- questions about risks, costs, or alternatives go unanswered
Before enrolling, you can discuss the trial with your healthcare providers and the research team. They can help you find official clinical trials and understand how participating in the trial may fit into your or your child’s MD care.
Muscular Dystrophy News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
